REGN

Regeneron Pharmaceuticals, Inc.

A fully integrated biotech that discovers and manufactures medicines for serious diseases, best known for EYLEA (for retinal conditions), Dupixent (for allergic and inflammatory diseases), and cancer drug Libtayo. Founded in 1988 by neurologist Leonard Schleifer and scientist George Yancopoulos, the company got its name by blending "regenerating neurons" with "gene" — reflecting its early dream of rebuilding damaged brain cells. It now grows drug-making cells in huge bioreactors at sites in New York and Ireland, and taps its own genetics center to find new drug targets.

CUSIP: 75886F107HealthcareUS5 holders

Ownership Activity Financials Filings

Insiders

Ranked by how much each holding moved in the last 5 years

Insider

Vagelos P RoyDirector · 22 transactions

1.15M-7.1%

as of Apr 2023

Granted 121.0K · Sold 28.6K

Yancopoulos GeorgeBd. Co-Chair, President & CSO, Director · 64 transactions

1.13M—

Granted 815.5K · Sold 150.5K

Schleifer Leonard SBd. Co-Chair, President & CEO, Director · 38 transactions

716.6K—

Granted 950.0K · Sold 94.8K

Stahl NeilEVP Research and Development · 59 transactions

59.3K—

as of Dec 2024

Granted 276.8K · Sold 48.7K

Murphy Andrew JEVP Research · 186 transactions

52.2K-12.9%

Granted 206.1K · Sold 53.8K

Larosa Joseph JEVP General Counsel and Secret · 49 transactions

45.6K—

Granted 158.2K · Sold 17.0K

Van Plew Daniel PEVP & General Mgr, Industrial · 106 transactions

35.2K—

Granted 266.1K · Sold 54.7K

Sing George LDirector · 43 transactions

33.2K-29.6%

Granted 20.9K · Sold 24.8K

Landry Robert EEVP Finance CFO · 178 transactions

24.0K-8.3%

as of Feb 2024

Granted 68.9K · Sold 11.8K

Fenimore Christopher R.EVP Finance CFO · 62 transactions

23.5K—

Granted 69.5K · Sold 22.4K

Ryan Arthur FDirector · 522 transactions

17.6K-25.1%

Granted 11.3K · Sold 14.2K

McCourt MarionEVP Commercial · 90 transactions

14.5K-15.2%

Granted 44.9K · Sold 35.9K

Brown Michael SDirector · 61 transactions

12.9K-17.7%

Granted 30.4K · Sold 31.1K

Goldstein Joseph LDirector · 13 transactions

6.7K+13.8%

Granted 12.0K · Sold 11.2K

Pitofsky JasonSVP Controller · 22 transactions

5.8K—

Granted 4.5K · Sold 3.0K

Poon Christine ADirector · 31 transactions

5.2K-61.7%

Granted 48.1K · Sold 44.6K

Zoghbi Huda YDirector · 27 transactions

3.2K+263.9%

Granted 7.6K · Sold 6.8K

Bassler Bonnie LDirector · 45 transactions

3.2K+259.5%

Granted 19.1K · Sold 18.3K

Tessier-Lavigne MarcDirector · 48 transactions

2.4K+17.1%

as of Jan 2023

Granted 47.5K · Sold 47.0K

Coles N AnthonyDirector · 41 transactions

1.7K+90%

Granted 24.5K · Sold 23.7K

Thompson Craig B.Director · 5 transactions

775—

Granted 775

Guarini KathrynDirector · 4 transactions

603—

Granted 603

Schenkein David PDirector · 4 transactions

603—

Granted 603

Insider	Stake change	Holds now	Granted / vested	Bought	Sold
Vagelos P RoyDirector · 22 transactions	-7.1%	1.15Mas of Apr 2023	121.0K	—	28.6K
Yancopoulos GeorgeBd. Co-Chair, President & CSO, Director · 64 transactions	—	1.13M	815.5K	—	150.5K
Schleifer Leonard SBd. Co-Chair, President & CEO, Director · 38 transactions	—	716.6K	950.0K	—	94.8K
Stahl NeilEVP Research and Development · 59 transactions	—	59.3Kas of Dec 2024	276.8K	—	48.7K
Murphy Andrew JEVP Research · 186 transactions	-12.9%	52.2K	206.1K	—	53.8K
Larosa Joseph JEVP General Counsel and Secret · 49 transactions	—	45.6K	158.2K	—	17.0K
Van Plew Daniel PEVP & General Mgr, Industrial · 106 transactions	—	35.2K	266.1K	—	54.7K
Sing George LDirector · 43 transactions	-29.6%	33.2K	20.9K	—	24.8K
Landry Robert EEVP Finance CFO · 178 transactions	-8.3%	24.0Kas of Feb 2024	68.9K	—	11.8K
Fenimore Christopher R.EVP Finance CFO · 62 transactions	—	23.5K	69.5K	—	22.4K
Ryan Arthur FDirector · 522 transactions	-25.1%	17.6K	11.3K	—	14.2K
McCourt MarionEVP Commercial · 90 transactions	-15.2%	14.5K	44.9K	—	35.9K
Brown Michael SDirector · 61 transactions	-17.7%	12.9K	30.4K	—	31.1K
Goldstein Joseph LDirector · 13 transactions	+13.8%	6.7K	12.0K	—	11.2K
Pitofsky JasonSVP Controller · 22 transactions	—	5.8K	4.5K	—	3.0K
Poon Christine ADirector · 31 transactions	-61.7%	5.2K	48.1K	—	44.6K
Zoghbi Huda YDirector · 27 transactions	+263.9%	3.2K	7.6K	—	6.8K
Bassler Bonnie LDirector · 45 transactions	+259.5%	3.2K	19.1K	—	18.3K
Tessier-Lavigne MarcDirector · 48 transactions	+17.1%	2.4Kas of Jan 2023	47.5K	—	47.0K
Coles N AnthonyDirector · 41 transactions	+90%	1.7K	24.5K	—	23.7K
Thompson Craig B.Director · 5 transactions	—	775	775	—	—
Guarini KathrynDirector · 4 transactions	—	603	603	—	—
Schenkein David PDirector · 4 transactions	—	603	603	—	—

Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.